Nanodesigning of multifunctional quantum dots and nanoparticles for the treatment of fibrosarcoma
An effective, dual drug(DD) loaded nanocarrier system (nano particle(NP), quantum dots(QDs)) having two active substances was aimed to develop for the treatment of fibrosarcoma. Zinc oxide(ZnO) QDs were produced using zinc acetate dehydrate as a precursor, were incorporated with chitosan(Ch), and finally decorated with PEG-linked folic acid and were found to be effective after imatinib mesylate(IM) and dexketoprofen trometamol(DT) were loaded. Characterisations, in vitro drug releases, cell toxicities, penetrations through cell lines and in-vivo animal tests of the prepared nanosystems were performed. The size of hybrid nanoparticles were 168.6 ± 48.8 nm, surface charge was -35.8 ± 0.26 mV. The encapsulation efficiency was 75% for IM and 99% for DT. DD-functionalised QDChNPs and lyophilised functionalised QDChNPs in capsules slowed down tumour growth by up to 76.5 and 88.7%. Our results demonstrate that developed hybrid nanoparticles are highly effective. This hybrid system gathers many of the advantages of nanotechnology into one form.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Journal of microencapsulation - 39(2022), 3 vom: 19. Mai, Seite 210-225 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Demirbolat, Gulen Melike [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9012-76-4 |
|---|
| Anmerkungen: |
Date Completed 06.07.2022 Date Revised 06.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/02652048.2021.1990423 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33334183X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33334183X | ||
| 003 | DE-627 | ||
| 005 | 20231225221452.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02652048.2021.1990423 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1111.xml |
| 035 | |a (DE-627)NLM33334183X | ||
| 035 | |a (NLM)34796787 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Demirbolat, Gulen Melike |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanodesigning of multifunctional quantum dots and nanoparticles for the treatment of fibrosarcoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2022 | ||
| 500 | |a Date Revised 06.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a An effective, dual drug(DD) loaded nanocarrier system (nano particle(NP), quantum dots(QDs)) having two active substances was aimed to develop for the treatment of fibrosarcoma. Zinc oxide(ZnO) QDs were produced using zinc acetate dehydrate as a precursor, were incorporated with chitosan(Ch), and finally decorated with PEG-linked folic acid and were found to be effective after imatinib mesylate(IM) and dexketoprofen trometamol(DT) were loaded. Characterisations, in vitro drug releases, cell toxicities, penetrations through cell lines and in-vivo animal tests of the prepared nanosystems were performed. The size of hybrid nanoparticles were 168.6 ± 48.8 nm, surface charge was -35.8 ± 0.26 mV. The encapsulation efficiency was 75% for IM and 99% for DT. DD-functionalised QDChNPs and lyophilised functionalised QDChNPs in capsules slowed down tumour growth by up to 76.5 and 88.7%. Our results demonstrate that developed hybrid nanoparticles are highly effective. This hybrid system gathers many of the advantages of nanotechnology into one form | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Imatinib mesylate | |
| 650 | 4 | |a ZnO quantum dots | |
| 650 | 4 | |a cancer treatment | |
| 650 | 4 | |a chitosan nanoparticles | |
| 650 | 4 | |a dexketoprofen trometamol | |
| 650 | 4 | |a fibrosarcoma | |
| 650 | 4 | |a synergetic effects | |
| 650 | 7 | |a Chitosan |2 NLM | |
| 650 | 7 | |a 9012-76-4 |2 NLM | |
| 650 | 7 | |a Zinc Oxide |2 NLM | |
| 650 | 7 | |a SOI2LOH54Z |2 NLM | |
| 700 | 1 | |a Altintas, Levent |e verfasserin |4 aut | |
| 700 | 1 | |a Yilmaz, Sukran |e verfasserin |4 aut | |
| 700 | 1 | |a Arsoy, Taibe |e verfasserin |4 aut | |
| 700 | 1 | |a Sözmen, Mahmut |e verfasserin |4 aut | |
| 700 | 1 | |a Degim, Ismail Tuncer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d 1989 |g 39(2022), 3 vom: 19. Mai, Seite 210-225 |w (DE-627)NLM013098217 |x 1464-5246 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:3 |g day:19 |g month:05 |g pages:210-225 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/02652048.2021.1990423 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 3 |b 19 |c 05 |h 210-225 | ||